An interventional study of ALIDYA in Cellulite and Gynoid Lipodystrophy, sponsored by Medical University of Silesia. Completed at 2 sites in Poland. Open to female participants aged 20 Years to 45 Years. Per ClinicalTrials.gov, last updated 2026-06-30.
Sponsored by Medical University of Silesia · Not applicable, Interventional, and Treatment
This study evaluated the efficacy of ALIDYA, a Class III medical device used in needle mesotherapy, for the treatment of cellulite (gynoid lipodystrophy) in women. Thirty female volunteers aged 20-45 years with cellulite graded 1 to 4 on the Nürnberger-Müller scale received a series of six mesotherapy treatments administered weekly to the posterior thighs. The study aimed to determine whether this treatment could improve the clinical appearance of cellulite and produce measurable changes in skin structure, microcirculation, and tissue composition. Assessments were performed before treatment, one month after the first application, and three months after the first application, using expert clinical grading as well as several objective instrumental methods: standardized clinical photography with texture analysis, thermal imaging, hyperspectral imaging, three-dimensional skin surface analysis (Antera 3D), and high-frequency ultrasound. The hypothesis was that ALIDYA would reduce the severity of cellulite by improving skin surface topography, microcirculation, and the structural quality of the skin.
ALIDYA is a Class III medical device manufactured by Marllor Biomedical (Italy), supplied as a 340 mg lyophilisate dissolved in 10 mL of solvent immediately before administration. The formulation is a polyamino acid gel containing gelatine hydrolysate, mannitol, calcium ascorbate, amino acids, EDTA, β-cyclodextrin, sodium chloride and sodium bicarbonate, and is intended to target the microcirculatory, oedematous, oxidative and fibrotic components of cellulite.
The treatment protocol consisted of six mesotherapy sessions performed at weekly intervals. The preparation was administered using a point-by-point microinjection technique into the dermis or upper subcutaneous layer, to a depth of approximately 4 mm, with a spacing of approximately 1.5 cm between injection sites, delivering 0.05-0.1 mL per point. Total volume per session was adjusted to body weight: 10 mL per session (5 mL per thigh) for participants under 70 kg, and 20 mL per session (10 mL per thigh) for participants 70 kg or over. The treatment area covered the posterior surfaces of both thighs, from approximately 5 cm above the popliteal fossa to the gluteal line.
Assessments were performed at baseline (T1), one month after the first application (T2), and three months after the first application (T3). Clinical assessment used the Nürnberger-Müller scale (C Level). Instrumental assessments included: standardized clinical photography under cross-polarized light with Gray-Level Co-occurrence Matrix (GLCM) texture analysis and Quadtree Decomposition (QTDCOMP) spatial analysis; thermal imaging analyzed via GLCM contrast and homogeneity; hyperspectral imaging (400-1000 nm) with extraction of haemoglobin-, water- and heterogeneity-related spectral metrics; three-dimensional skin surface analysis (Antera 3D) for indentation volume, texture, and erythema; and high-frequency ultrasound (22 MHz) for skin thickness and acoustic density.
71 studies on the registry are indexed under Cellulite; 3 are open to participants now.
This study's enrollment of 30 is below the median of 34 across 65 interventional studies indexed under Cellulite.
Browse Cellulite studies →Medical University of Silesia is the lead sponsor of 115 studies on the registry; 26 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
All 30 participants received a series of six needle mesotherapy treatments with ALIDYA, administered at weekly intervals to the posterior surfaces of both thighs. The preparation was injected intradermally or into the upper subcutaneous tissue at a depth of approximately 4 mm, using a point-by-point technique with 0.05-0.1 mL administered per injection site. Total volume per session was 10 mL (5 mL per thigh) for participants under 70 kg, or 20 mL (10 mL per thigh) for participants 70 kg or over. Assessments were performed at baseline (T1), one month after the first application (T2), and three months after the first application (T3).
Device: ALIDYA
ALIDYA is supplied as a 340 mg lyophilisate, dissolved in 10 mL of solvent immediately before administration to form an injectable solution. The formulation is a polyamino acid gel containing gelatine hydrolysate, mannitol, calcium ascorbate, amino acids, EDTA, β-cyclodextrin, sodium chloride and sodium bicarbonate. It was administered via needle mesotherapy, in a series of six sessions at weekly intervals, with 0.05-0.1 mL injected per site, and a total session volume of 10 mL or 20 mL depending on body weight (\<70 kg or ≥70 kg, respectively).
Change from Baseline in Cellulite Severity (C Level) at 3 Months
Cellulite severity was assessed by an expert using the Nürnberger-Müller scale, scored from 0 (no cellulite) to 4 (maximum changes), based on visual assessment in the standing position and palpation, taking into account skin unevenness, depressions, nodules, and the 'orange peel' sign.
Time frame: Baseline (T1) and 3 months after the first application (T3)
Change from Baseline in GLCM Contrast and Homogeneity of Skin Photographic Images at 3 Months
Skin texture was assessed using Gray-Level Co-occurrence Matrix (GLCM) analysis of standardized clinical photographs taken under cross-polarized light. GLCM Contrast quantifies local brightness variation (higher values indicate more pronounced surface irregularities); GLCM Homogeneity quantifies overall image uniformity (higher values indicate smoother, more even skin). Both parameters were assessed separately for the left and right thigh.
Time frame: Baseline (T1), 1 month (T2), and 3 months after the first application (T3)
Change from Baseline in Quadtree Decomposition Fragmentation Indices of Skin Photographic Images at 3 Month
Skin surface fragmentation was assessed using Quadtree Decomposition (QTDCOMP) analysis of standardized clinical photographs, which divides the image into homogeneous square blocks ranging from 2×2 to 128×128 pixels. A higher number of small squares (2×2 to 32×32 pixels) indicates greater structural fragmentation and irregularity, typical of more severe cellulite. A higher number of large squares (64×64 and 128×128 pixels) indicates smoother, more homogeneous skin areas. Square counts were assessed separately for the left and right thigh
Time frame: Baseline (T1), 1 month (T2), and 3 months after the first application (T3)
Change from Baseline in Thermal Imaging GLCM Contrast and Homogeneity at 3 Months
Skin thermal texture was assessed using Gray-Level Co-occurrence Matrix (GLCM) analysis of infrared thermograms. GLCM Contrast quantifies local temperature variation (higher values indicate greater thermal heterogeneity, e.g. adjacent hypothermic and hyperthermic skin areas typical of cellulite). GLCM Homogeneity quantifies overall thermal map uniformity (higher values indicate more even temperature distribution). Both parameters were assessed separately for the left and right thigh.
Time frame: Baseline (T1), 1 month (T2), and 3 months after the first application (T3)
Change from Baseline in Hyperspectral Reflectance and Signal Heterogeneity Indices at 3 Months
Skin optical properties were assessed using hyperspectral imaging (400-1000 nm) via dimensionless reflectance-based indices. Metrics included: mean reflectance in the haemoglobin-sensitive band (500-570 nm) and near-infrared range (700-900 nm); depth of the haemoglobin absorption dip at \~560 nm (HbDepth560); reflectance ratio indices R560/R650 and R577/R650; the water index (970/800 nm); and signal heterogeneity metrics (mean spread, standard deviation of spread, coefficient of variation of spread) describing spatial variability within the region of interest. All metrics are dimensionless ratios or proportions. An increase in reflectance and ratio indices, a decrease in haemoglobin dip depth, and a decrease in heterogeneity metrics were interpreted as indicating improved microcirculation and reduced optical heterogeneity of the skin.
Time frame: Baseline (T1), 1 month (T2), and 3 months after the first application (T3)
Change from Baseline in Hyperspectral Spectral Slope at 3 Months
Skin optical properties were assessed using hyperspectral imaging (400-1000 nm) via the slope of the reflectance curve, expressed in units of reflectance change per nanometer (1/nm). Spectral slope was measured in the visible range (500-600 nm) and near-infrared range (700-900 nm). An increase in slope was interpreted as a change in the overall shape of the reflectance spectrum, associated with reduced haemoglobin-related absorption (visible range) or altered scattering and tissue structure (near-infrared range).
Time frame: Baseline (T1), 1 month (T2), and 3 months after the first application (T3)
Change from Baseline in Skin Indentation Volume (Antera 3D) at 3 Months
Skin surface depressions were assessed using the Antera 3D imaging system, which measures the volume of skin indentations (Volume, in mm³) within the region of interest. A higher Volume value indicates greater depth and extent of skin depressions, corresponding to more pronounced cellulite. A decrease in Volume was interpreted as a favorable reduction in skin depression depth and surface smoothing. Volume was assessed separately for the left and right thigh.
Time frame: Baseline (T1), 1 month (T2), and 3 months after the first application (T3)
Change from Baseline in Skin Texture Score and Roughness (Antera 3D) at 3 Months
Skin surface texture was assessed using the Antera 3D imaging system, which measures two dimensionless parameters: Texture Score (a composite measure of textural abnormality severity) and Roughness (degree of surface irregularity). Higher values for both parameters indicate greater skin unevenness; a decrease following treatment was interpreted as surface smoothing and reduced severity of skin micro-relief. Both parameters were assessed separately for the left and right thigh.
Time frame: Baseline (T1), 1 month (T2), and 3 months after the first application (T3)
Change from Baseline in Skin Texture Maximum Height (Antera 3D) at 3 Months
Skin surface texture was assessed using the Antera 3D imaging system, which measures Texture Maximum Height (in mm), the greatest height difference within the region of interest. A higher value indicates greater skin unevenness; a decrease following treatment was interpreted as surface smoothing and reduced severity of skin micro-relief. This parameter was assessed separately for the left and right thigh.
Time frame: Baseline (T1), 1 month (T2), and 3 months after the first application (T3)
Change from Baseline in Skin Erythema Parameters (Antera 3D) at 3 Months
Skin erythema was assessed using the Antera 3D imaging system, which measures four parameters: Redness Score (overall erythema intensity), Minimum and Maximum (lower and upper range of erythema signal intensity), and Uniformity (uniformity of erythema distribution within the region of interest). A decrease in Redness Score, Minimum, and Maximum was interpreted as a reduction in the vascular-erythemal component of cellulite. All parameters were assessed separately for the left and right thigh.
Time frame: Baseline (T1), 1 month (T2), and 3 months after the first application (T3)
Change from Baseline in Skin Thickness (Ultrasound) at 3 Months
Skin structure was assessed using high-frequency (22 MHz) ultrasound, which measures Skin Thickness (in mm), the distance from the entry echo to the dermal-subcutaneous boundary. An increase in Skin Thickness was interpreted as a favorable sign of dermal remodeling and increased collagen matrix organization. This parameter was assessed separately for the left and right thigh.
Time frame: Baseline (T1), 1 month (T2), and 3 months after the first application (T3)
Change from Baseline in Skin Acoustic Density (Ultrasound) at 3 Months
Skin structure was assessed using high-frequency (22 MHz) ultrasound, which measures Acoustic Density/Echogenicity (in IU), reflecting the degree of ultrasound wave reflection by tissue matrix structures. An increase in Acoustic Density was interpreted as a favorable sign of increased collagen matrix organization and reduced interstitial oedema. This parameter was assessed separately for the left and right thigh.
Time frame: Baseline (T1), 1 month (T2), and 3 months after the first application (T3)
Plan to share: No
This study is completed, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Medical University of Silesia →